Tuğçe DURAN, Ali Ahmed AZZAWRİ, İbrahim Halil YILDIRIM

Timokinon meme kanseri hücrelerinde Bax/BAD ve Bcl-2 yolakları aracılığıyla apoptozu uyarmaktadır

Amaç: Bazı eski tıbbi kaynaklarda çeşitli terapötik yararlarından bahsedilen ve yaygın olarak kara tohum ismiyle bilinen Nigellasativa, modern bilim tarafından da onaylanmış ve halk hekimliğinde de kullanılmakta olan bir bitkidir. Timokinon, Nigellasativa tohumu yağının ana bileşiği ve temel etken maddesidir. Timokinon’un, anti-oksidan, antienflamatuar ve anti-tümör özellikleri dahil olmak üzere hücreleri etkileyen bazı mekanizmalar ile yüksek biyolojik aktiviteye ve geniş terapötik potansiyele sahip olduğu rapor edilmiştir. Her ne kadar Timokinon’un, hücre büyümesini ve proliferasyonunu inhibe ettiği ve çeşitli kanser hücrelerinde apoptozu uyardığı yaygın olarak bildirilmişse de, mekanizmalar ve sinyal yolakları tam olarak anlaşılmamıştır. Bu çalışmadaki amacımız, Timokinon’unapoptoz üzerindeki etkisini hem tümör ve hem de non-tümör hücrelerde ortaya koymaktır. Yöntemler: Bu çalışmada, tümör hücreleri olarak meme kanseri hücreleri olan MCF-7 hücreleri, non-tümör hücreler olarak da Human Embrionic Kidney Cell (HEK293) hücreleri kullanıldı. Hücrelerin canlılık analizi, Timokinon uygulaması sonrasında MTT analizi ile gerçekleştirildi. Bax, BAD, Bcl-2 ve p53 gibi apoptoz belirteçlerinin gen ekspresyonu Real-Time PCR ile belirlendi. Bulgular ve Sonuç: Sonuçlar, Timokinon'un hücre çoğalması ve canlılığı üzerinde güçlü bir etkisi olduğunu göstermektedir. Timokinon, apoptozu indükleyen BAD ve Bax genlerinin ekspresyonunu arttırmış ve meme kanseri hücrelerinde p53 geni ekspresyonunu azaltmıştır. Bu nedenle, Timokinon’unapoptozu destekleyerek meme kanseri hücrelerinde anti-kanser etkinliğini arttırdığı sonucuna varılmıştır.

Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells

Objective: Nigella sativa, commonly known as the black seed, has been used since ancient times in folk medicine, andits various therapeutic benefits have been mentioned in some ancient medical sources and confirmed by modernscience. Thymoquinone is the major compound and essential active ingredient of Nigella sativa seed oil.Thymoquinone has been reported to have high biological activity and broad therapeutic potential through severalmechanisms that affect cells including anti-oxidant, anti-inflammatory, and anti-tumor properties. Although it hasbeen widely reported that Thymoquinone inhibits cell growth and proliferation and stimulates apoptosis in varioustypes of cancer cells, the mechanisms and signaling pathways are not fully understood. The aim of this study was todetermine the effect of Thymoquinone on apoptosis in both tumor and non-tumor cells.Methods: In this study, breast cancer cell line (MCF-7) was used as tumor cells and Human Embryonic Kidney Cell line(HEK293) was used as non-tumor cells. Cells were treated with Thymoquinone and viability test performed by MTTassay.Gene expression of apoptosis markers such as Bax, BAD, Bcl-2, and p53 was determined by Real-Time PCR.HEK293 cells were used as non-tumor control.Results and Conclusion: Results suggest that Thymoquinone has a strong effect on cell proliferation and vitality.Thymoquinone has increased the expression of BAD, Bax genes which induce apoptosis and decreased the p53 gene inbreast cancer cells. Therefore Thymoquinone promotes apoptosis and enhances anti-cancer efficacy in breast cancercells.

PDF

___

1. Yeo B, Turner NC, Jones A. An update on the medical management of breast cancer. BMJ 2014;348:g3608.
2. Becker S. A historic and scientific review of breast cancer: The next global healthcare challenge. Int J Gynecol Obstet. 2015;131: 36-9.
3. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006; 8:216.
4. Chen MC, Lee NH, Hsu HH, et all. Thymoquinone induces caspase-independent, autophagic cell death in CPT-11-resistant lovo colon cancer via mitochondrial dysfunction and activation of JNK and p38. J. Agric. Food Chem. 2015;63:1540-6.
5. Gali-Muhtasib HU, AbouKheir WG, Kheir LA, Darwiche N, Crooks PA. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs, 2004;15: 389-99.
6. Banerjee S, Padhye S, Azmi A, et all. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer. 2010; 62: 938-46.
7. Burits M, Bucar F. Antioxidant activity of Nigella sativa essential oil. Phytother Res. 2000; 14: 323-8.
8. Ali B, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003; 17:299-305.
9. Badary OA, Taha RA, Gamal el-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. Drug ChemToxicol. 2003;26:87-98.
10. El Gazzar M, El Mezayen R, Marecki JC, et all. Antiinflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. IntImmunopharmacol. 2006; 6: 1135-42.
11. Worthen DR, Ghosheh OA, Crooks PA. The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res. 1998;18: 1527–32.
12. Jafri SH, Glass J, Shi R, et all. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J ExpClin Cancer Res. 2010; 29:87.
13. Li F, Rajendran P, Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol. 2010;161:541–54.
14. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myoloblastic leukemia HL-60 cells. Int J Cancer. 2005;117: 409-17.
15. Gali-Muhtasib H, Diab-Assaf M, Boltze C, et all. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. IntJ Onco. 2004; 25: 857-66.
16. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2: 533-43.
17. Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol. 2011; 4:687-99.
18. Hata AN, Engelman JA, Faber AC. The BCL-2 family: key mediators of the apoptotic response to targeted anti-cancer therapeutics. Cancer Discov. 2015; 5: 475-87.
19. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for BclXL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285–91
20. Scheid MP, Schubert KM, Duronio V. Regulation of Bad Phosphorylation and Association with Bcl-xL by the MAPK/Erk Kinase. The Journal of Biological Chemistry. 1999; 274: 31108-13.
21. Kocak N, Yildirim IH, YildirimCing S, Cellular functions of p53 and p53 gene family members p63 and p73, Dicle Medical Journal, 2011; 38:530-35.
22. Marjaneh M, Narazah MY, Shahrul H. Apoptosis pathway targeted by thymoquinone in MCF7 breast cancer cell line. International Scholarly and Scientific Research & Innovation 2015; 9:87-91.
23. Arafa ESA, Zhu Q, Shah ZI, et all.,Thymoquinone upregulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat. Res. 2011;706: 128–35.
24. Woo CC, Hsu A, Kumar AP, Sethi G, Tan KH. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS One. 2013 Oct 2; 8:e75356. doi: 10.1371/journal.pone.0075356. eCollection 2013.
25. Shanmugam MK, Ahn KS, Hsu A, et all., Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis. Front Pharmacol. 2018 Dec 4;9:1294. doi: 10.3389/fphar.2018.01294
26. Mostofa AGM, Hossain MK, Basak D, Bin Sayeed MS. Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies. Front Pharmacol. 2017 Jun 12;8:295. doi: 10.3389/fphar.2017.00295. eCollection 2017.
27. Kabel AM, El-Rashidy MA, Omar MS (2016) Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical Study. Cancer Med Anticancer Drug 1:102. doi:10.4172/cmacd.1000102
28. Bashmail HA, Alamoudi AA, Noorwali A, et all., Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities. Scientific Reports 2018; volume 8, Article number: 11674.
29. Alobaedi OH, Talib WH, Basheti IA. Antitumor effect of thymoquinone combined with resveratrol on mice transplanted with breast cancer. Asian Pasific Journal of Tropical Medicine 2017; 10: 400-8.